Takeyama M, Ikawa K, Nagano T, Mori K
Department of Clinical Pharmacy, Oita Medical University, Japan.
J Pharm Pharmacol. 1996 Jun;48(6):657-9. doi: 10.1111/j.2042-7158.1996.tb05991.x.
Elcatonin, used for treatment of hypercalcaemia, Paget's disease and osteoporosis, causes flushing of the face and hands. To determine whether this was because of increased levels of vasoactive intestinal peptide, which is known to induce vasodilation, the effect of elcatonin on the plasma levels of vasoactive intestinal peptide was studied in five healthy volunteers. After a single intramuscular administration of elcatonin (20 int units), peak plasma elcatonin levels (approx. 30 pg mL-1) were achieved 30 min after injection. Plasma vasoactive intestinal peptide concentrations rose similarly with peak levels of about 17 pg mL-1 after 30 min. Side-effects such as cutaneous flushing (most obvious in the face and hands) occurred to an extent dependent on the amount of elcatonin administered, and declined over 45 min in parallel with the fate of plasma vasoactive intestinal peptide. The side-effects of elcatonin, especially cutaneous flushing, seem to be closely connected with vasoactive intestinal peptide.
用于治疗高钙血症、佩吉特病和骨质疏松症的降钙素会导致面部和手部潮红。为了确定这是否是由于已知可诱导血管舒张的血管活性肠肽水平升高所致，在五名健康志愿者中研究了降钙素对血管活性肠肽血浆水平的影响。单次肌内注射降钙素（20国际单位）后，注射后30分钟达到血浆降钙素峰值水平（约30 pg/mL）。血浆血管活性肠肽浓度也类似地升高，30分钟后峰值水平约为17 pg/mL。皮肤潮红（在面部和手部最明显）等副作用的发生程度取决于降钙素的给药量，并在45分钟内与血浆血管活性肠肽的变化情况平行下降。降钙素的副作用，尤其是皮肤潮红，似乎与血管活性肠肽密切相关。
